EMA PRAC Warns of Aseptic Meningitis Risk with Ixchiq Vaccine

Fri, 13 Mar 2026 12:40:35 +0000
Pharmaceuticals

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended updating the product information for the chikungunya vaccine Ixchiq to reflect recent evidence of aseptic meningitis risk, particularly in healthy young adults. This follows a safety signal investigation and is part of a regular safety assessment.